Epilepsy market set to stagnate in Europe
This article was originally published in Scrip
As the market for epilepsy drugs emerges from the first patent cliff that eroded much of its value over 2008–09, Datamonitor Healthcare has been evaluating its prospects over the coming years. The value of the epilepsy market will undergo steady growth in the US and Japan, but – despite a spate of recent launches – in the five major EU markets it is likely to remain flat.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.